[go: up one dir, main page]

PL3482767T3 - Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy - Google Patents

Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy

Info

Publication number
PL3482767T3
PL3482767T3 PL18199358T PL18199358T PL3482767T3 PL 3482767 T3 PL3482767 T3 PL 3482767T3 PL 18199358 T PL18199358 T PL 18199358T PL 18199358 T PL18199358 T PL 18199358T PL 3482767 T3 PL3482767 T3 PL 3482767T3
Authority
PL
Poland
Prior art keywords
replacement therapy
dose escalation
enzyme replacement
acid sphingomyelinase
treating acid
Prior art date
Application number
PL18199358T
Other languages
English (en)
Inventor
Edward H. Schuchman
Robert J. Desnick
Gerald F. Cox
Laura P. Andrews
James M. Murray
Original Assignee
Icahn School Of Medicine At Mount Sinai
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3482767(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icahn School Of Medicine At Mount Sinai, Genzyme Corporation filed Critical Icahn School Of Medicine At Mount Sinai
Publication of PL3482767T3 publication Critical patent/PL3482767T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
PL18199358T 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy PL3482767T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
EP10812683.0A EP2470199B1 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
EP18199358.5A EP3482767B1 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number Publication Date
PL3482767T3 true PL3482767T3 (pl) 2022-02-14

Family

ID=43625265

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18199358T PL3482767T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
PL10812683T PL2470199T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10812683T PL2470199T3 (pl) 2009-08-28 2010-08-28 Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy

Country Status (29)

Country Link
US (9) US8349319B2 (pl)
EP (3) EP3482767B1 (pl)
JP (8) JP5955219B2 (pl)
KR (5) KR102094253B1 (pl)
CN (3) CN105999238A (pl)
AU (6) AU2010286550B2 (pl)
BR (1) BR112012004377A2 (pl)
CA (1) CA2773133A1 (pl)
CL (1) CL2012000495A1 (pl)
CY (1) CY1122128T1 (pl)
DK (3) DK2470199T3 (pl)
ES (2) ES2738859T3 (pl)
FI (2) FI3998078T3 (pl)
FR (1) FR22C1062I2 (pl)
HR (2) HRP20191385T1 (pl)
HU (3) HUE046598T2 (pl)
IL (4) IL314807A (pl)
LT (3) LT3482767T (pl)
LU (1) LUC00288I2 (pl)
MX (2) MX392330B (pl)
NL (1) NL301211I2 (pl)
NO (1) NO2022054I1 (pl)
PL (2) PL3482767T3 (pl)
PT (3) PT3998078T (pl)
RU (2) RU2731616C2 (pl)
SI (2) SI2470199T1 (pl)
TR (1) TR201911293T4 (pl)
WO (1) WO2011025996A2 (pl)
ZA (2) ZA201201435B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
PT3252161T (pt) 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
WO2011146143A2 (en) 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
SI2753346T1 (sl) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidaza in diferenciacija celic
JP6243846B2 (ja) 2011-11-15 2017-12-06 セントジーン アーゲー ニーマン・ピック病の診断のための方法
HUE051020T2 (hu) 2012-06-01 2021-01-28 Icahn School Med Mount Sinai A ceramid szintjei a fertõzések kezelésében és megelõzésében
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
WO2014183873A1 (en) * 2013-05-14 2014-11-20 Centogene Ag Method for the diagnosis of niemann-pick disease
PL3004896T3 (pl) * 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
SG11202001544VA (en) * 2017-08-24 2020-03-30 Sanofi Sa Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
FR3070383B1 (fr) 2017-08-31 2021-08-20 Solable Appareil de traitement d'eau
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
TW202142236A (zh) 2020-02-03 2021-11-16 美商健臻公司 用於治療與溶體儲積症相關的神經症狀之方法
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
MXPA01006491A (es) 1998-12-23 2003-06-06 Thompson Boyce Plant Res Expresion de antigenos de superficie de hepatitis b inmunogenicos en plantas transgenicas.
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2002018539A2 (en) * 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
AU2003224880A1 (en) * 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CN101027388A (zh) * 2003-06-12 2007-08-29 建新公司 具有增强活性的修饰的人酸性神经磷脂酶及其制备方法
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN1897957A (zh) 2003-11-25 2007-01-17 纽约大学西奈山医学院 尼曼－皮克病的基于陪伴分子的治疗
DE602005021379D1 (de) 2004-10-13 2010-07-01 Protalix Ltd System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
CA2634042A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
CA2641359C (en) * 2006-02-09 2022-10-04 Genzyme Corporation Slow intraventricular delivery
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
WO2008136451A1 (ja) 2007-04-27 2008-11-13 Nagase & Co., Ltd. スフィンゴミエリナーゼ
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
PL3004896T3 (pl) * 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania
SG11202001544VA (en) * 2017-08-24 2020-03-30 Sanofi Sa Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients

Also Published As

Publication number Publication date
RU2012111823A (ru) 2013-10-10
AU2020256322B2 (en) 2024-02-29
NO2022054I1 (no) 2022-12-01
KR20120081077A (ko) 2012-07-18
JP5955219B2 (ja) 2016-07-20
US8349319B2 (en) 2013-01-08
FR22C1062I1 (fr) 2023-02-03
NL301211I2 (nl) 2023-02-02
US9655954B2 (en) 2017-05-23
US9114139B2 (en) 2015-08-25
FIC20220051I1 (fi) 2022-12-20
HUS2200050I1 (hu) 2022-12-28
CN105999238A (zh) 2016-10-12
LT2470199T (lt) 2019-10-10
US20140335070A1 (en) 2014-11-13
US10188705B2 (en) 2019-01-29
AU2024201085A1 (en) 2024-03-07
US20160120957A1 (en) 2016-05-05
EP3482767B1 (en) 2021-10-06
US20110052559A1 (en) 2011-03-03
US20220305091A1 (en) 2022-09-29
RU2015145255A (ru) 2019-01-11
KR20230164773A (ko) 2023-12-04
AU2016216625A1 (en) 2016-09-15
FR22C1062I2 (fr) 2023-12-29
AU2020256322A1 (en) 2020-11-12
EP2470199B1 (en) 2019-05-22
PT3482767T (pt) 2021-12-29
US20210077593A1 (en) 2021-03-18
JP2023012499A (ja) 2023-01-25
EP3998078B1 (en) 2025-10-01
SI3482767T1 (sl) 2022-03-31
WO2011025996A3 (en) 2012-03-15
IL300625A (en) 2023-04-01
US20180055916A1 (en) 2018-03-01
CN102596232A (zh) 2012-07-18
HRP20191385T1 (hr) 2019-11-01
MX356873B (es) 2018-06-18
DK2470199T3 (da) 2019-08-05
JP7395693B2 (ja) 2023-12-11
JP7605949B2 (ja) 2024-12-24
CA2773133A1 (en) 2011-03-03
LTC3482767I2 (pl) 2024-03-25
KR102608551B1 (ko) 2023-12-04
PT3998078T (pt) 2025-11-07
IL218324A0 (en) 2012-04-30
ZA201601362B (en) 2017-05-31
IL266915A (en) 2019-07-31
US8658162B2 (en) 2014-02-25
US8709408B2 (en) 2014-04-29
KR102893390B1 (ko) 2025-11-28
KR102094253B1 (ko) 2020-03-31
EP2470199A2 (en) 2012-07-04
ES2738859T3 (es) 2020-01-27
ZA201201435B (en) 2020-05-27
JP2024026214A (ja) 2024-02-28
JP2022003065A (ja) 2022-01-11
IL300625B1 (en) 2024-09-01
CL2012000495A1 (es) 2014-02-07
EP2470199A4 (en) 2013-03-27
IL218324B (en) 2019-05-30
AU2010286550A1 (en) 2012-03-15
IL266915B1 (en) 2023-03-01
AU2016216625B2 (en) 2018-07-05
KR20200034828A (ko) 2020-03-31
TR201911293T4 (tr) 2019-08-21
HUE046598T2 (hu) 2020-03-30
FI3998078T3 (fi) 2025-12-04
NL301211I1 (nl) 2022-12-28
CN106047835A (zh) 2016-10-26
RU2569744C2 (ru) 2015-11-27
RU2020128994A (ru) 2022-03-02
IL300625B2 (en) 2025-01-01
KR20220104271A (ko) 2022-07-26
ES2902229T3 (es) 2022-03-25
US20130078230A1 (en) 2013-03-28
LT3482767T (lt) 2022-01-10
PL2470199T3 (pl) 2019-11-29
MX2012002449A (es) 2012-03-14
WO2011025996A2 (en) 2011-03-03
AU2025205539A1 (en) 2025-08-07
KR20210107153A (ko) 2021-08-31
JP6952810B2 (ja) 2021-10-20
JP2018076322A (ja) 2018-05-17
SI2470199T1 (sl) 2019-11-29
EP3482767A1 (en) 2019-05-15
RU2731616C2 (ru) 2020-09-07
DK3482767T3 (da) 2021-12-20
PT2470199T (pt) 2019-08-07
IL266915B2 (en) 2023-07-01
RU2015145255A3 (pl) 2019-08-12
BR112012004377A2 (pt) 2017-12-12
MX392330B (es) 2025-03-11
HRP20211992T1 (hr) 2022-04-01
KR102608546B1 (ko) 2023-12-04
DK3998078T3 (da) 2025-11-17
US20130078231A1 (en) 2013-03-28
JP7167281B2 (ja) 2022-11-08
CY1122128T1 (el) 2020-11-25
WO2011025996A9 (en) 2011-08-25
JP2020090513A (ja) 2020-06-11
AU2018204156B2 (en) 2020-07-16
JP2025038063A (ja) 2025-03-18
EP3998078A1 (en) 2022-05-18
AU2018204156A1 (en) 2018-06-28
AU2024201085B2 (en) 2025-04-24
JP6251307B2 (ja) 2017-12-20
AU2010286550B2 (en) 2016-05-19
US20190151419A1 (en) 2019-05-23
LUC00288I2 (pl) 2025-05-12
JP2013502933A (ja) 2013-01-31
IL314807A (en) 2024-10-01
HUE057440T2 (hu) 2022-05-28
JP2016153408A (ja) 2016-08-25

Similar Documents

Publication Publication Date Title
IL266915A (en) Increasing dose replacement enzyme for the treatment of acid sphingomyelinase deficiency
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
IL215393A0 (en) Therapy for promoting cell growth
IL253293B (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
SG10201507199UA (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
IL275350B (en) Treatment of neoplastic diseases
HUE043235T2 (hu) Terápiás kezelések tüdõbetegségekhez
EP2675472A4 (en) METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
SI2473172T1 (sl) Bisfosfonat sestavki in postopki za zdravljenje srčne okvare
ZA201301279B (en) Preventive or therapeutic agent for fibrosis
ZA201009063B (en) Diaryl ureas for treating heart failure
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
EP2604264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRUS DISEASES
GB0909239D0 (en) Targeted gene therapy
IL218160A0 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders